Developing Drugs for Sarcomas in a Brave New World-Reference-Cited by-同舟云学术

Developing Drugs for Sarcomas in a Brave New World

Published:2020-05-01 Issue:2 Volume:3 Page:62-63
ISSN:2590-017X
Container-title:Journal of Immunotherapy and Precision Oncology
language:en
Short-container-title:

Author:

Loong Herbert H.¹

Affiliation:

1. Department of Clinical Oncology, Phase 1 Clinical Trial Centre, CUHK/PWH Adult Sarcoma Multidisciplinary Team, The Chinese University of Hong Kong, Hong Kong

Publisher

Innovative Healthcare Institute

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://meridian.allenpress.com/innovationsjournals-JIPO/article-pdf/3/2/62/2517127/i2590-017x-3-2-62.pdf

Reference12 articles.

1. Loong HH, Blay JY, Munhoz RR. International collaborations and regional challenges in providing specialist multidisciplinary sarcoma care. Am Soc Clin Oncol Educ Book. 2019; 39: 616– 623.

2. Ryan CW, Merimsky O, Agulnik M, et al. PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma. J Clin Oncol. 2016; 34: 3898– 3905.

3. Tap WD, Papai Z, Van Tine BA, et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017; 18: 1089– 1103.

4. Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016; 388: 488– 497.

5. Tap WD, Wagner AJ, Papai Z, et al. ANNOUNCE: a randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS). J Clin Oncol.2019; 37: LBA3-LBA.